Relationship between metabolic toxicity and efficacy of everolimus in patients with neuroendocrine tumors: A pooled analysis from the randomized, phase 3 RADIANT-3 and RADIANT-4 trials.

Nicola FazioCarlo CarnaghiRoberto BuzzoniJuan W ValleFabian HerbstAntonia RidolfiJonathan StrosbergMatthew H KulkeMarianne E PavelJames C Yao

Published in: Cancer (2021)

Although limitations apply because of the small number of AEs observed, there was no significant impact of these AEs on PFS; this suggests similar efficacy in the presence or absence of these events.

Keyphrases

neuroendocrine tumors
double blind
open label
oxidative stress
placebo controlled
clinical trial
randomized controlled trial
oxide nanoparticles